Jeff L. Vacirca, Director at Caris Life Sciences, Inc. (CAI), bought 31,050 shares at $16.15 ($501K) on 2026-05-11, disclosed to the SEC on 2026-05-12.
Director Jeff L. Vacirca purchased 31,050 shares of Caris Life Sciences for $501,426, marking the largest insider purchase in the company's history. This significant buyback occurs as the stock trades 60% below its 52-week high, suggesting insiders see value in the precision oncology leader despite a 70% year-to-date decline.
The stock is currently trading at $16.77, down 22% over the last 90 days and a staggering 70% over the past year. It sits 60.54% below its 52-week high of $42.50 but is only 6.75% above its 52-week low of $15.71.
Clearly above the average filing.
| Filing → |
| ODT | BUY | 2019-06-28 | $500K | — | Filing → |
| ODT | BUY | 2019-03-07 | $51K | — | Filing → |
| ODT | BUY | 2017-12-14 | $23K | — | Filing → |